The FDA cleared MiniMed Fit on Nov. 16, 2026, days after Tandem Mobi went tubeless. How seven day wear, 300 units and pharmacy access reshape patch pumps.
Last updated: November 17, 2026
MiniMed won FDA clearance for MiniMed Fit, its first tubeless insulin pump, on November 16, 2026, three days after Tandem Diabetes Care announced clearance of a tubeless Tandem Mobi. Both promise up to seven days of wear, sold through pharmacies, and both launch in 2027 against Insulet’s three day Omnipod 5.
Scope: what the two clearances cover, how the devices compare on paper, what changes for prescribers, payers and the pump business, and what to watch before the 2027 launches.
What did the FDA clear for MiniMed and Tandem?
The FDA cleared two tubeless automated insulin delivery options in one week. MiniMed Fit is a new patch pump from MiniMed, the diabetes company Medtronic finished spinning off in October. Tandem Mobi tubeless is not a new pump: it is a new infusion set and cartridge that let the existing Mobi pump stick to the body.
MiniMed announced the MiniMed Fit clearance on Monday, November 16, 2026. The company says the pump offers up to seven days of wear and a 300 unit insulin capacity, and is cleared for people with Type 1 and Type 2 diabetes ages 7 and older. At launch it will pair with MiniMed’s own Simplera Sync sensor (up to seven days of wear) and with Instinct, a sensor made by Abbott (up to 15 days of wear). Its SmartGuard algorithm can deliver correction doses every five minutes, and the pump carries MiniMed’s Meal Detection feature, which MedTech Dive describes as adding insulin when a meal bolus is missed or underestimated.
Tandem announced its clearance on Friday, November 13, 2026, calling Tandem Mobi “the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear.” The fine print matters: Tandem’s release says the tubeless infusion set is cleared for up to 7 days of wear and the cartridge for 3 days of use. MiniMed’s release, issued three days later, makes a near identical “world’s first and only” claim in its headline for MiniMed Fit as a tubeless insulin pump with up to seven days of wear. Both claims are the companies’ own; neither release names the FDA pathway used.
How do MiniMed Fit, Tandem Mobi tubeless and Omnipod 5 compare?
On paper, MiniMed Fit holds the most insulin and the longest single wear claim, Tandem’s edge is that existing Mobi users need no new pump, and Omnipod 5 matches Tandem on the lowest age floor while holding a head start in pharmacies. The table below uses only each company’s own published specifications.
| Feature | MiniMed Fit | Tandem Mobi tubeless | Insulet Omnipod 5 |
|---|---|---|---|
| Status | FDA cleared, announced Nov 16, 2026 | FDA cleared, announced Nov 13, 2026 | On the US market |
| Wear claim | Up to 7 days | Infusion set up to 7 days; cartridge 3 days | Up to 72 hours per Pod |
| Insulin capacity | 300 units | 200 unit cartridge | Up to 200 units |
| Label population | Type 1 and Type 2, ages 7 and older | Pump ages 2 and older; Control-IQ+ for Type 1 ages 2 and older, Type 2 ages 18 and older | Type 1 ages 2 and older; Type 2 ages 18 and older |
| Sensors named | Simplera Sync; Abbott Instinct | Compatible iCGMs (no brand named in the release) | Dexcom G6 and G7; FreeStyle Libre 2 Plus and 3 Plus |
| Channel | Pharmacy | Pharmacy, for customers with pharmacy benefits | Pharmacy |
| US timing | Early customer phase in MiniMed’s fiscal Q4 2027, phased rollout spring 2027 | Full commercial launch in the first half of 2027 | Available now |
Sources: MiniMed release (Nov 16, 2026), Tandem release (Nov 13, 2026), Insulet’s Omnipod 5 product and pharmacy pages (accessed Nov 17, 2026). No company published a price.
Why does seven day wear matter?
Wear time sets how often a patient changes hardware and how many units a pharmacy ships each month. A pump that stays on for seven days instead of three cuts site changes by more than half, which is the convenience argument both companies are leading with.
Capacity is the quiet constraint. A seven day patch only lasts seven days if it holds enough insulin for the wearer’s weekly dose. MiniMed’s 300 unit reservoir gives it more room than a 200 unit design. Tandem solves the same problem differently: its patch stays on for up to seven days, but the 200 unit cartridge is changed every three days. For clinicians, that means the honest comparison is total daily insulin dose against reservoir size, patient by patient, not the headline wear number.
Why are all three selling through the pharmacy?
Pharmacy distribution has become the model for tubeless pumps because it turns the device into a recurring supply, closer to how insulin itself is bought. Insulet already sells Omnipod 5 this way and says most patients pay less than $30 a month for supplies, with over a third paying nothing, per its own pharmacy page.
Tandem says its tubeless supplies will be sold exclusively through the pharmacy for customers with pharmacy benefits, a channel it says covers about 50% of insured lives in the United States. MiniMed says MiniMed Fit will be available through the pharmacy channel. Insulet’s own page calls Omnipod 5 the first and only tubeless automated insulin delivery system indicated for Type 1 and Type 2 diabetes available through the pharmacy. In 2027 that lane gets two challengers, which gives payers and pharmacy benefit managers real competition for formulary position.
What does this mean for MiniMed after the Medtronic split?
MiniMed Fit arrives about a month after Medtronic completed its exit from MiniMed on October 15, 2026, and it puts the newly independent company head to head with Tandem in tubeless pumps, as MedTech Dive framed it, while both chase Insulet’s installed base.
CEO Que Dallara told a September investor conference that MiniMed does not think it is “just another entrant,” according to MedTech Dive. The timeline is the test: MiniMed puts its early customer phase in its fiscal fourth quarter of 2027 and the phased US rollout in spring 2027, so revenue from MiniMed Fit is a 2027 story, not a 2026 one.
What does this mean for Tandem after its Mobi recall?
Tandem’s clearance lands weeks after a Class I recall on the same pump family. FDA’s recall database lists recall Z-0316-2027 for Tandem Mobi as Class 1, initiated September 23 and posted October 30, covering 80,938 units, with a cause listed as process change control; patients were told they could keep using the pump. MedTech Dive reported, citing a Tandem spokesperson, 230 adverse events and no deaths.
The clearance itself does not resolve that recall. What it does give Tandem is an upgrade path: the company says customers with an in warranty Mobi will not need a new pump, they switch the infusion set and cartridge. Leerink Partners analysts called Mobi tubeless the company’s “single most important commercial catalyst and growth driver,” as quoted by MedTech Dive.
Our framework: what each stakeholder should check before 2027
- Endocrinology practices: map current patients by total daily insulin dose against 200 and 300 unit capacities; confirm which sensor each patient already uses, since MiniMed Fit launches with Simplera Sync and Abbott Instinct only.
- Pediatric clinics: note the label floor. MiniMed Fit is cleared from age 7; Omnipod 5 and the Mobi pump from age 2.
- Payers and PBMs: expect three tubeless products seeking pharmacy coverage in 2027; ask each for supply cost per month at real wear patterns, not best case wear.
- Hospital and DME buyers: track which products move out of the durable equipment channel entirely.
- Investors and strategists: watch launch metrics in the first half of 2027, Tandem recall closure, and any Insulet response on wear time or capacity.
- Quality and regulatory teams: the Mobi recall is a reminder that a component change can trigger a Class I event; treat the new tubeless cartridge and set as a fresh change control file.
What to watch next
- MiniMed’s early customer experience phase and the start of its phased US rollout in spring 2027.
- Tandem’s limited launch and the full commercial launch in the first half of 2027.
- Pricing and pharmacy coverage decisions for both products, which neither company has disclosed.
- FDA recall database updates on Tandem Mobi recall Z-0316-2027.
- Whether Insulet updates Omnipod 5 wear time, capacity or sensor support in response.
- Additional sensor integrations for MiniMed Fit beyond the two named at launch.
FAQ
What is MiniMed Fit?
MiniMed Fit is MiniMed’s first tubeless insulin pump, cleared by the FDA and announced November 16, 2026. The company says it offers up to seven days of wear, a 300 unit insulin capacity, and automated dosing through its SmartGuard algorithm.
Who can use MiniMed Fit?
MiniMed says the pump is cleared for people with Type 1 and Type 2 diabetes ages 7 and older.
When will MiniMed Fit be available?
MiniMed plans a phased US rollout in spring 2027, following an early customer experience phase expected in its fourth quarter of fiscal year 2027. It will be sold through the pharmacy channel.
Which glucose sensors work with MiniMed Fit?
At commercial launch, MiniMed says MiniMed Fit works with its Simplera Sync sensor and with Abbott’s Instinct sensor.
Is Tandem Mobi tubeless a new pump?
No. Tandem says the clearance covers a new tubeless infusion set and cartridge for the existing Tandem Mobi, and customers with an in warranty Mobi will not need a new pump.
How long does Tandem Mobi tubeless last before a change?
Tandem says the tubeless infusion set is cleared for up to 7 days of wear and the cartridge for 3 days of use.
How does Omnipod 5 compare?
Insulet says each Omnipod 5 Pod delivers insulin for up to 72 hours and holds up to 200 units. It is indicated for Type 1 diabetes from age 2 and Type 2 diabetes from age 18.
Do the new tubeless pumps cost less?
Neither MiniMed nor Tandem has published a price. Both say supplies will be sold through the pharmacy, so out of pocket cost will depend on each patient’s pharmacy benefit.
Does the FDA clearance affect the Tandem Mobi recall?
No. The recall, listed by the FDA as Class 1 and covering 80,938 units, is a separate action from the new clearance.
Are these devices really the first with seven day wear?
Both companies make a “world’s first and only” claim with seven day wear in their own releases, worded differently. Those are company claims, not FDA statements.
Sources
Primary
- MiniMed, “FDA Clears MiniMed Fit,” PR Newswire release, Northridge, Calif., November 16, 2026 (news.minimed.com).
- Tandem Diabetes Care, “Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear,” Business Wire release, San Diego, November 13, 2026 (investor.tandemdiabetes.com).
- Insulet, Omnipod 5 healthcare professional product page and pharmacy page, omnipod.com, accessed November 17, 2026.
- FDA medical device recall database, recall Z-0316-2027 (Tandem Mobi), posted October 30, 2026.
Attributed
- MedTech Dive, “MiniMed gets FDA nod for tubeless insulin pump,” November 16, 2026 (Dallara September conference remarks, meal detection description).
- MedTech Dive, “Tandem wins FDA clearance for tubeless automated insulin delivery system,” November 16, 2026 (Leerink Partners and William Blair analyst views).
- MedTech Dive, “Tandem recalls Mobi insulin pump, reports 230 adverse events,” November 2026 (230 adverse events, no deaths, per a Tandem spokesperson).
Related coverage
- FDA device recall classes explained, including the Tandem Mobi Class I recall
- Medtronic completes the MiniMed separation
- Embecta’s insulin patch pump clearance for Type 2 diabetes
- What a PMA not approvable letter means for device makers
- Siemens Healthineers carves out diagnostics as Olyrian
- BioMed Nexus company directory
Get the daily briefing that connects these stories: subscribe to BioMed Nexus.


